Rapolas Žilionis, Chief Scientific Officer at Atrandi Biosciences introduced a new high-throughput single-cell analysis platform using semi-permeable capsules which combine the versatility of microwell plates with the throughput of droplet microfluidics, enabling multi-step reactions with simple lab equipment.
The novelty in this technology is the use of capsules which consist of a liquid core and a semi permeable hydrogel shell. The hydrogel shell will retain cells and nucleic acids and allow smaller molecules, DNTPs, proteins and buffer components to diffuse through freely. Furthermore, the capsules are robust, can withstand harsh conditions, and allow for multiple reaction steps, including PCR and cell lysis, without risk of coalescence. All of the above make the platform highly adaptable, allowing for both upscaling and downscaling. It is also suitable for a wide range of applications, from growing cell colonies to performing multi-step reactions.
A key innovation is the simultaneous sequencing of single-cell RNA and DNA (amplicon panels), providing both genotypic and phenotypic data from the same cell. This is particularly valuable for applications such as validating CRISPR edits, cancer research, and studying viral infections at the single-cell level. The workflow involves encapsulating cells, performing lysis and reverse transcription, followed by PCR amplification of both transcriptome and targeted DNA regions. Barcoding enables tracking of individual cells throughout the process.
The proof-of-concept experiments demonstrated the platform’s ability to distinguish cell types and genotypes in mixed donor samples, with high efficiency in detecting both RNA and DNA targets. The results highlighted the importance of careful amplicon panel design for uniform detection. Žilionis concluded by explaining that the technology is available for innovators to develop custom workflows, and Atrandi Biosciences welcomes feedback to refine panel design and experiment scale.
